Uncovering Negative Results: Introducing an Open Access Journal “Journal of Pharmaceutical Negative Results”
Vipra Kundoor1★, Mueen Ahmed KK2★ Corresponding author
- 1U. S. Food and Drug Administration, Rockville, Maryland, USA.
- 2Department of Pharm Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, KINGDOM OF SAUDI ARABIA.
CORRESPONDENCE
Vipra Kundoor
U. S. Food and Drug Administration, Rockville, Maryland, USA.
Volume 2, Issue 4 · pp. 339–341 · PUBLISHED · DOI: 10.4103/0975-1483.71618
ABSTRACT
Drug discovery nowadays is a highly innovative process by which new drugs are discovered and/or designed. It is expected that in the year 2010, at least 50% of all new approved drugs will come from the biopharmaceutical sector. The discovery and validation process is mostly carried out by new innovative and medium-sized companies. But, despite advances in technology and greater understanding of biological systems, drug discovery is still a lengthy process. Specialized drug discovery companies need an ideal business climate, that is, political, economic and social conditions, to be able to cope with the entrepreneurial risks of drug development.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kundoor, V., & KK, M. A. (). Uncovering Negative Results: Introducing an Open Access Journal “Journal of Pharmaceutical Negative Results”. Journal of Young Pharmacists, 2(4), 339–341. https://doi.org/10.4103/0975-1483.71618